WO2015182570A1 - 熱安定性が改善されたセロビオハイドロラーゼ - Google Patents
熱安定性が改善されたセロビオハイドロラーゼ Download PDFInfo
- Publication number
- WO2015182570A1 WO2015182570A1 PCT/JP2015/064994 JP2015064994W WO2015182570A1 WO 2015182570 A1 WO2015182570 A1 WO 2015182570A1 JP 2015064994 W JP2015064994 W JP 2015064994W WO 2015182570 A1 WO2015182570 A1 WO 2015182570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- thermal stability
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
- C12N9/2437—Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/12—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01091—Cellulose 1,4-beta-cellobiosidase (3.2.1.91)
Definitions
- the present invention relates to a thermostable cellobiohydrolase with improved thermostability and applied technology thereof.
- Cellulases which are cellulolytic enzymes, can be broadly divided into cellobiohydrase (also referred to as “CBH” in this document) that acts on the crystalline region of cellulose and endoglucanase that acts from the inside of the cellulose molecular chain to reduce the molecular weight. It is done.
- ⁇ -glucosidase is an enzyme that acts on a water-soluble oligosaccharide or cellobiose to catalyze a reaction of hydrolyzing its ⁇ -glycoside bond.
- CBH is classified into two types, CBHI and CBHII, depending on the mode of action.
- CBHI is an enzyme classified as GH7, which is cleaved at the cellobiose unit from the reducing end of the cellulose chain to form a tunnel structure having four long loops covering the active site and the substrate binding site. Therefore, the cocoon cellulose chain passes through this tunnel and is cleaved by cellobiose from the end.
- CBHII is classified as GH6 and is an enzyme that cleaves at the cellobiose unit from the non-reducing end of the cellulose chain.
- an object of the present invention is to provide CBHI having more excellent thermal stability.
- amino acid sequence represented by SEQ ID NO: 1 an amino acid sequence having 85% or more identity with the amino acid sequence represented by SEQ ID NO: 1, or a substitution or insertion of one or several amino acids in the amino acid sequence represented by SEQ ID NO: 1,
- mutation (A) and / or (B) (A) one or more amino acid substitutions selected from the group consisting of S42Q, T43E, K45T, S46A, G47P, N53Q, S54N, T262G, S298P, A426P, and V451F; (B) substitution of the amino acid region of positions 413 to 416 in the amino acid sequence shown in SEQ ID NO: 1 with the amino acid sequence shown in SEQ ID NO: 2; And Cellobiohydrolase activity, and improved thermal stability, Having a polypeptide.
- Item 2. A polynucleotide encoding the polypeptide according to Item 1.
- Item 3. An expression vector incorporating the polynucleotide according to Item 2.
- Item 4. A transformant transformed with the vector according to Item 3.
- Item 5. Item 4.
- Item 6. A method for producing cellobiose, comprising a step of allowing the polypeptide of Item 1 to act on a sample containing cellulose.
- cellobiohydrolase having excellent thermostability is provided. Therefore, biomass can be efficiently saccharified by using the present invention.
- FIG. 1 shows the results of measuring the residual activity of CBHI after heat treatment.
- FIG. 2 shows the results of examining the optimum temperatures of mutant 6 and wild-type CBHI when microcrystalline cellulose is used as a substrate.
- amino acid sequence shown in SEQ ID NO: 1 is an amino acid sequence constituting wild-type CBHI derived from the filamentous fungus Talaromyces cerulolyticus, and this sequence is known.
- CBHI with improved thermal stability is 1 in the amino acid sequence shown in SEQ ID NO: 1, the amino acid sequence having 85% or more identity with the amino acid sequence shown in SEQ ID NO: 1, or the amino acid sequence shown in SEQ ID NO: 1.
- it is preferable that it is a polypeptide which has an amino acid sequence containing the specific amino acid substitution mentioned later in the amino acid sequence by which several amino acid was substituted, inserted, added, and / or deleted.
- amino acid sequence having 85% or more identity with the amino acid sequence shown in SEQ ID NO: 1 and “one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1 are substituted, inserted, added, And / or “deleted amino acid sequence” may be collectively referred to as “amino acid sequence corresponding to SEQ ID NO: 1”.
- the calculation can be performed by using default (initial setting) parameters in Basic • Local • Alignment • Search • Tool (BLAST) of National • Center • for • Biotechnology • Information (NCBI).
- the amino acid sequence having 85% or more identity with the amino acid sequence shown in SEQ ID NO: 1 preferably has 90% or more identity with the amino acid sequence shown in SEQ ID NO: 1, more preferably It has 95% or more identity with the amino acid sequence shown in SEQ ID NO: 1, more preferably 98% identity or more with the amino acid sequence shown in SEQ ID NO: 1, and still more preferably shown in SEQ ID NO: 1. And 99% or more identity with the amino acid sequence.
- amino acid sequence in which one or several amino acids are substituted, inserted, added, and / or deleted in the amino acid sequence shown in SEQ ID NO: 1 means that CBHI is a cellobiohydrolase activity. And as long as it has improved thermal stability, it is not particularly limited, for example, 50, 45, 30, 25, 20, 15, 10, 5, 3, or 2. The “several” herein does not include the number of substituted amino acids added to improve the thermal stability described later.
- the type of substitution is not particularly limited, but has a significant negative influence on the higher-order structure, phenotype or characteristics of the polypeptide. From the viewpoint of not giving a conservative amino acid substitution is preferable.
- Constant amino acid substitution refers to substitution of an amino acid residue with an amino acid residue having a side chain of similar properties.
- the amino acid residue is a basic side chain (for example, lysine, arginine, histidine), an acidic side chain (for example, aspartic acid, glutamic acid), an uncharged polar side chain (for example, glycine, asparagine, glutamine, serine, Threonine, tyrosine, cysteine), non-polar side chains (eg, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (eg, threonine, valine, isoleucine), aromatic side chains ( For example, it can be classified into tyrosine, phenylalanine, tryptophan, histidine). Therefore, the amino acid substitution is preferably performed between other amino acid residues belonging to the same category as the amino acid present in the original amino acid sequence.
- substitution here is different from the substitution added to improve the thermal stability described later.
- Mutations such as amino acid substitutions, deletions, insertions and / or additions occur in regions that do not significantly affect the higher order structure of the polypeptide or in regions that are not directly involved in catalytic activity (eg, regions other than the active center). It is preferred that Examples of such a region include a region exposed on the surface of the protein.
- Techniques for adding mutations such as substitution, deletion, insertion or addition of one or several amino acids to a specific amino acid sequence are known in the art, and can be performed using any method. For example, restriction enzyme treatment, treatment with exonuclease or DNA ligase, position-directed mutagenesis, random mutagenesis, etc. can be used.
- Substitutions added to improve the thermal stability of CBHI are (A) from S42Q, T43E, K45T, S46A, G47P, N53Q, S54N, T262G, S298P, A426P, and V451F.
- the symbols representing the respective substitutions in (A) above the numbers mean the amino acid positions in the amino acid sequence of SEQ ID NO: 1.
- the alphabet before the number means the type of amino acid originally present at that position.
- the alphabet after the number means the type of amino acid that replaces the naturally occurring amino acid.
- S42Q means that the 42nd serine (S) in the amino acid sequence of SEQ ID NO: 1 is substituted with glutamine (Q). The same applies to symbols representing other substitutions.
- amino acid sequence at positions 413 to 416 in the amino acid sequence shown in SEQ ID NO: 1 is NATG (SEQ ID NO: 11), and is shown by SEQ ID NO: 2 that replaces this region.
- the amino acid sequence is DADPT.
- amino acid substitutions (A) and (B) only one type may be added to the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence corresponding thereto, or the amino acid sequence of SEQ ID NO: 1 in combination of two or more types Alternatively, it may be added to the corresponding amino acid sequence.
- the combination is arbitrary.
- the number of amino acid substitutions to be combined is also arbitrary, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more , 11 or more, or all 12 types.
- preferred amino acid substitution combinations are S42Q, T43E, K45T, S46A, G47P, N53Q, and S54N.
- a preferred amino acid substitution combination in one embodiment is T262G, S298P, and A426P in one embodiment.
- preferred amino acid substitution combinations are T262G, S298P, A426P, N413D, T415D, and G416P.
- the polypeptide has improved thermal stability. Improved thermostability refers to having higher thermal stability compared to wild type CBHI having the amino acid sequence of SEQ ID NO: 1 (ie, inactivated over wild type CBHI under the same temperature conditions). Meaning difficult).
- Thermal stability can be measured by any method.
- the protein-thermal-shift assay Kerishita et al., Protein-Expr Purif. Can be requested.
- the denaturation temperature of wild-type CBHI is 63 ° C., and thus CBHI with improved thermal stability preferably has a denaturation temperature higher than 63 ° C.
- Such denaturation temperatures are, for example, 64 ° C or higher, 65 ° C or higher, 66 ° C or higher, 67 ° C or higher, 68 ° C or higher, 69 ° C or higher, 70 ° C or higher, 71 ° C or higher, 72 ° C or higher, 73 ° C or higher, 74 More than 75 degreeC and 75 degreeC or more.
- Thermal stability can be evaluated based on the residual activity after heat treatment by holding CBHI at a certain temperature for a predetermined time (heat treatment) and measuring the enzyme activity before and after that. If the residual activity is higher than the residual activity of wild-type CBHI, it can be evaluated that the thermal stability is improved.
- CBHI has a residual activity of preferably 50% or more, more preferably 55% or more, and more preferably 60% or more when held at 65 ° C. for 5 minutes. More preferably, it is more preferably 70% or more.
- activity and “enzyme activity” mean cellobiohydrolase activity, unless otherwise indicated.
- a method for measuring cellobiohydrolase activity is known, and any method can be selected and measured.
- a method of measuring free PNP using a synthetic substrate PNP-Lac as a substrate, which is employed in Examples described later, can be mentioned.
- a polypeptide which is CBHI with improved thermal stability can be produced by genetic engineering techniques using a polynucleotide encoding it.
- the polypeptide can also be produced using general protein chemical synthesis methods (for example, liquid phase method and solid phase method) based on the amino acid sequence information shown in SEQ ID NO: 1. .
- a polynucleotide encoding a polypeptide that is CBHI with improved thermal stability is based on the nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and the type and position of the introduced substitution and other mutations. And can be easily obtained using a chemical DNA synthesis method (for example, phosphoramidite method) or a genetic engineering technique.
- the polynucleotide is preferably a polynucleotide that is present in an isolated state.
- the base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 is known.
- the above-described polypeptide can be produced by incorporating the above-described polynucleotide into an arbitrary vector in an expressible state, introducing it into a host suitable for the type of the vector, and expressing it.
- the vector type can be appropriately selected in consideration of the host cell type.
- a plasmid vector, a cosmid vector, a phage vector, a virus vector for example, an adenovirus vector, a retrovirus vector, a herpes virus vector, etc.
- a virus vector for example, an adenovirus vector, a retrovirus vector, a herpes virus vector, etc.
- the host cell used for introducing the expression vector is not particularly limited as long as the polypeptide can be produced, and may be either a prokaryotic cell or a eukaryotic cell.
- Escherichia coli bacteria such as Escherichia coli (for example, HB101, MC1061, JM109, CJ236, MV1184 etc.), coryneform bacteria such as Corynebacterium glutamicum, actinomycetes such as Streptomyces bacteria, Prokaryotic cells such as Bacillus bacteria such as Bacillus subtilis, Streptococcus bacteria, Staphylococcus bacteria; Yeasts such as Saccharomyces, Pichia and Kluyveromyces, Aspergillus, Penicillium, Trichoderma and Acremonium And other fungal cells; insect cells such as Drosophila S2, Spodoptera Sf9, and silkworm cultured cells; and plant cells.
- Polypeptides can also be produced in the medium using the protein secret
- the method for introducing the expression vector into the host cell can be carried out by a conventionally used method.
- a conventionally used method examples thereof include various methods such as a competent cell method, a protoplast method, an electroporation method, a microinjection method, and a liposome fusion method.
- Specific examples of the method for introduction into coryneform bacteria include the protoplast method (Gene, 39, 281-286 (1985)) and the electroporation method (Bio / Technology, 7, 1067-1070) (1989)). Etc. can be used, but is not limited thereto.
- a host cell for example, a transformant into which an expression vector has been introduced can be used to produce a polypeptide that is CBHI having improved thermostability.
- the transformant can also be used as it is for saccharification of biomass containing cellulose.
- the production of the polypeptide using the transformant can be carried out by culturing the transformant and recovering the polypeptide from the culture.
- the culture can be performed by subculture or batch culture using a medium suitable for the host. Culturing can be carried out until an appropriate amount is obtained using the activity of the polypeptide produced inside or outside the transformant as an index.
- various media commonly used according to the host cell can be appropriately selected and used, and the culture can be performed under conditions suitable for the growth of the host cell.
- a nutrient medium such as an LB medium or a medium obtained by adding a carbon source, a nitrogen source, a vitamin source or the like to a minimal medium such as an M9 medium can be used for culturing Escherichia coli.
- Culture conditions can also be set as appropriate according to the type of host. Usually, the cells are cultured at 16 to 42 ° C., preferably 25 to 37 ° C. for 5 to 168 hours, preferably 8 to 72 hours. Depending on the host, either shaking culture or stationary culture is possible, but stirring may be performed as necessary, and aeration may be performed. When an inducible promoter is used, the culture can be performed by adding a promoter inducer to the medium.
- Purification or isolation of the polypeptide from the culture can be performed by appropriately combining known techniques. For example, ammonium sulfate precipitation, ethanol or other solvent precipitation, dialysis, ultrafiltration, acid extraction, and various chromatography (eg gel filtration chromatography, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography) , Affinity chromatography, hydroxyapatite chromatography and lectin chromatography, high performance liquid chromatography, etc.).
- a carrier used for affinity chromatography for example, a carrier to which an antibody against the polypeptide is bound, or a carrier to which a substance having an affinity for the tag is bound when a tag is added to the polypeptide. You can also.
- the transformed cells can be disrupted and purified or isolated from the centrifuged supernatant of the disrupted product in the same manner as described above.
- the cells collected by centrifugation are suspended in a cell disruption buffer (20-100 mM Tris-HCl (pH 8.0), 5 mM EDTA), subjected to ultrasonic disruption, and the disruption treatment solution is 10,000.
- the supernatant can be obtained by centrifugation at ⁇ 15000 rpm for 10-15 minutes.
- the precipitate after centrifugation can be further purified after solubilization with guanidinium hydrochloride or urea, if necessary.
- the biomass resource By bringing the polypeptide into contact with a sample containing cellulose (for example, a cellulosic biomass resource), the biomass resource can be decomposed to produce a sugar solution.
- a sugar solution can also be produced more efficiently by using an enzyme such as another cellulase together.
- the type of cellulosic biomass is not particularly limited as long as it can be decomposed by CBHI.
- Examples thereof include bagasse, wood, bran, wheat straw, rice straw, rice bran, soybean meal, soybean okara, coffee cake, rice cake, and the like. Can do.
- the temperature condition can be set to 5 to 90 ° C., preferably 15 to 80 ° C., more preferably 30 to 75 ° C., more preferably 50 to 70 ° C. or 50 to 65 ° C.
- temperature conditions can be set to 63 degreeC or more, 64 degreeC or more, 65 degreeC or more, and 66 degreeC or more.
- the pH can be carried out under conditions of pH 4-9.
- the amount of polypeptide to be added is not particularly limited, and can be, for example, in the range of 0.1 to 0.5% (w / w).
- a gene (polynucleotide) encoding CBHI derived from Talalomyces cerulolyticus was cloned and ligated downstream of the starch-inducible glucoamylase promoter and the CBHI signal sequence derived from the same organism to construct an expression plasmid vector (Inoueouet al , J. Ind. Microbiol. Biotechnol., 2013, 40: 823-830). Escherichia coli (DH5 ⁇ ) was transformed with this expression vector. The obtained plasmid was purified, and mutations were introduced into the gene by the quick change method using this plasmid as a template.
- mutants were prepared using the primer sets shown in Table 1 below alone or in combination: mutation in which threonine at position 262 was replaced with glycine in the amino acid sequence represented by SEQ ID NO: 1 Body 1; Mutant 2 in which serine at position 298 is replaced with proline; Mutant 3 in which alanine at position 426 is replaced with proline; Asparagine at position 413 is replaced with aspartic acid and threonine at position 415 4 in which is substituted with aspartic acid and glycine at position 416 is replaced with proline; mutant 5 in which mutations 1 to 3 are combined; mutant in which mutations 1 to 4 are combined 6; Serine at position 42 is replaced with glutamine, threonine at position 43 is replaced with glutamic acid, lysine at position 45 is replaced with threonine, Mutant 7 wherein serine at position 6 is substituted with alanine, glycine at position 47 is replaced with proline, asparagine at position 53
- a primer set (F1 and F2) corresponding to substitution of amino acids at positions 42 to 47 and a primer set (F2 and F2) corresponding to substitution of amino acids at positions 53 and 54 was used.
- the sequence of the gene into which the mutation was introduced was confirmed by sequencing, and Talaromyces cerrolyticus was transformed with the plasmid in which each gene was incorporated.
- the transformant was cultured in a starch medium, and mutant CBHI was secreted outside the cells.
- the culture broth was collected and ammonium sulfate was added so as to be 60% saturated.
- the precipitate was collected with a centrifuge, dissolved in 20 mM MES buffer (pH 6.5), and then desalted using a desalting column HiPrep desalting 26/10 equilibrated with the same buffer.
- the desalted sample was applied to an ion exchange column ResourceQ equilibrated with 20 mM MES buffer (pH 6.5) and eluted with 20 mM MES buffer (pH 6.5) containing 1 M sodium chloride. After adding ammonium sulfate so that the elution fraction showing CBH1 activity becomes 1.2 M, it was applied to a hydrophobic column Resource Iso equilibrated with 20 mM sodium acetate buffer (pH 5.5) containing 1.2 M ammonium sulfate, and 20 mM. Elution with sodium acetate buffer (pH 5.5) and concentration of active fractions were concentrated. For this section, it was confirmed that SDS-PAGE showed a single band, and purification was completed. The enzyme purified in this way was measured for heat resistance and activity.
- the enzyme activity was determined by measuring the released PNP using the synthetic substrate PNP-Lac.
- the heat resistance is the denaturation temperature (Tm) at which the three-dimensional structure of the enzyme protein changes using the protein thermal shift assay (TSA) described in Kishishita et al., (Protein Expr Purif. 2014 Feb; ) Was measured and evaluated.
- TSA protein thermal shift assay
- TSA was performed using each CBHI mutant enzyme dissolved in 20 mM sodium acetate buffer (pH 5.0). The measurement results are shown in Table 2 below.
- mutants 1 to 8 all had improved heat resistance (thermal stability) compared to the wild-type enzyme.
- thermal stability the improvement in thermal stability was remarkable.
- mutants 1 to 8 have a slightly reduced enzyme activity compared to wild type, but are negligible considering the improved thermal stability.
- a 20 mM sodium acetate buffer (pH 5.0) containing either wild type CBHI or mutants 1 to 8 at a concentration of 0.02 to 0.05 mg / ml was prepared. This was maintained at a temperature of 65 ° C., and after 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 60 minutes, and 90 minutes, a part of the enzyme solution was taken out and its remaining activity was reduced to 45%. Measured at ° C. The substrate was 1 mM PNP-Lactose and the same measurement method as described above was used. The residual activity was calculated with the activity at the start of treatment at 65 ° C. (that is, 0 minute) as 100%. The results are shown in FIG. As shown in FIG.
- mutants 6 and 8 showed no decrease in activity even after 60 minutes.
- mutant 6 and wild type CBHI were examined using microcrystalline cellulose (Avicel) (FIG. 2).
- Mutant 6 and wild-type CBHI were reacted in a buffer solution (pH 5.0) containing a microcrystalline cellulose (Avicel) substrate at 50 ° C. to 75 ° C. for 2 hours, and the solubilized sugar released was quantified by reducing power. .
- FIG. 2 it was confirmed that the mutant 6 has an optimum temperature higher than that of the wild type even when microcrystalline cellulose is used as a substrate. Similar trends are expected for other mutants.
Abstract
Description
項1.
配列番号1に示されるアミノ酸配列、配列番号1に示されるアミノ酸配列と85%以上の同一性を有するアミノ酸配列、或いは配列番号1に示されるアミノ酸配列において1又は数個のアミノ酸が置換、挿入、付加、及び/又は欠失されたアミノ酸配列において、下記(A)及び/又は(B)の変異:
(A)S42Q、T43E、K45T、S46A、G47P、N53Q、S54N、T262G、S298P、A426P、及びV451Fから成る群より選択される1種以上のアミノ酸置換;
(B)配列番号1に示されるアミノ酸配列における第413位~第416番目のアミノ酸領域の配列番号2で示されるアミノ酸配列との置換;
を有し、且つ、
セロビオハイドロラーゼ活性、及び
改善された熱安定性、
を有する、ポリペプチド。
項2.
項1に記載のポリペプチドをコードするポリヌクレオチド。
項3.
項2に記載のポリヌクレオチドを組み込んだ発現ベクター。
項4.
項3に記載のベクターで形質転換された形質転換体。
項5.
項4に記載の形質転換体を培養する工程を含む、項1に記載のポリペプチドの製造方法。項6.
項1に記載のポリペプチドをセルロースを含む試料に作用させる工程を含む、セロビオースを製造する方法。
Claims (6)
- 配列番号1に示されるアミノ酸配列、配列番号1に示されるアミノ酸配列と85%以上の同一性を有するアミノ酸配列、或いは配列番号1に示されるアミノ酸配列において1又は数個のアミノ酸が置換、挿入、付加、及び/又は欠失されたアミノ酸配列において、下記(A)及び/又は(B)の変異:
(A)S42Q、T43E、K45T、S46A、G47P、N53Q、S54N、T262G、S298P、A426P、及びV451Fから成る群より選択される1種以上のアミノ酸置換;
(B)配列番号1に示されるアミノ酸配列における第413位~第416番目のアミノ酸領域の配列番号2で示されるアミノ酸配列との置換;
を有し、且つ、
セロビオハイドロラーゼ活性、及び
改善された熱安定性、
を有する、ポリペプチド。 - 請求項1に記載のポリペプチドをコードするポリヌクレオチド。
- 請求項2に記載のポリヌクレオチドを組み込んだ発現ベクター。
- 請求項3に記載のベクターで形質転換された形質転換体。
- 請求項4に記載の形質転換体を培養する工程を含む、請求項1に記載のポリペプチドの製造方法。
- 請求項1に記載のポリペプチドをセルロースを含む試料に作用させる工程を含む、セロビオースを製造する方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016523493A JP6441330B2 (ja) | 2014-05-27 | 2015-05-26 | 熱安定性が改善されたセロビオハイドロラーゼ |
US15/313,784 US10047351B2 (en) | 2014-05-27 | 2015-05-26 | Cellobiohydrolase having improved thermal stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014109035 | 2014-05-27 | ||
JP2014-109035 | 2014-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015182570A1 true WO2015182570A1 (ja) | 2015-12-03 |
Family
ID=54698896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/064994 WO2015182570A1 (ja) | 2014-05-27 | 2015-05-26 | 熱安定性が改善されたセロビオハイドロラーゼ |
Country Status (3)
Country | Link |
---|---|
US (1) | US10047351B2 (ja) |
JP (1) | JP6441330B2 (ja) |
WO (1) | WO2015182570A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515506A (ja) * | 2002-08-16 | 2006-06-01 | ジェネンコー・インターナショナル・インク | 新規なハイプロクレアジェコリーナcbh1セルラーゼ |
JP2012039967A (ja) * | 2010-08-20 | 2012-03-01 | Toyota Central R&D Labs Inc | 耐熱性セロビオヒドロラーゼ及びその利用 |
WO2012104239A1 (en) * | 2011-01-31 | 2012-08-09 | Dsm Ip Assets B.V. | Mutant cellobiohydrolase |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4257759B2 (ja) | 1999-07-06 | 2009-04-22 | 明治製菓株式会社 | 新規なプロモーター、及びそれを用いたタンパク質の発現方法 |
NZ571087A (en) * | 2006-02-10 | 2012-04-27 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
CA2811789A1 (en) * | 2010-10-06 | 2012-04-12 | Bp Corporation North America Inc. | Variant cbh i polypeptides with reduced product inhibition |
WO2013103127A1 (ja) | 2012-01-06 | 2013-07-11 | 本田技研工業株式会社 | 糖化酵素組成物及びそれを用いる糖化溶液の製造方法 |
-
2015
- 2015-05-26 WO PCT/JP2015/064994 patent/WO2015182570A1/ja active Application Filing
- 2015-05-26 JP JP2016523493A patent/JP6441330B2/ja active Active
- 2015-05-26 US US15/313,784 patent/US10047351B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006515506A (ja) * | 2002-08-16 | 2006-06-01 | ジェネンコー・インターナショナル・インク | 新規なハイプロクレアジェコリーナcbh1セルラーゼ |
JP2012039967A (ja) * | 2010-08-20 | 2012-03-01 | Toyota Central R&D Labs Inc | 耐熱性セロビオヒドロラーゼ及びその利用 |
WO2012104239A1 (en) * | 2011-01-31 | 2012-08-09 | Dsm Ip Assets B.V. | Mutant cellobiohydrolase |
Non-Patent Citations (3)
Title |
---|
FANG X. ET AL.: "Strain improvement of Acremonium cellulolyticus for cellulase production by mutation.", J. BIOSCI. BIOENG., vol. 107, no. 3, 2009, pages 256 - 261, XP026006824, ISSN: 1389-1723 * |
GUSAKOV A.V.: "Alternatives to Trichoderma reesei in biofuel production.", TRENDS BIOTECHNOL., vol. 29, no. 9, 2011, pages 419 - 425 * |
VOUTILAINEN S.P. ET AL.: "Expression of Talaromyces emersonii cellobiohydrolase Cel7A in Saccharomyces cerevisiae and rational mutagenesis to improve its thermostability and activity.", PROTEIN ENG. DES. SEL., vol. 23, no. 2, 2010, pages 69 - 79, XP002642935 * |
Also Published As
Publication number | Publication date |
---|---|
JP6441330B2 (ja) | 2018-12-19 |
JPWO2015182570A1 (ja) | 2017-04-20 |
US20170191048A1 (en) | 2017-07-06 |
US10047351B2 (en) | 2018-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007244753B2 (en) | Thermostable cellulase and methods of use | |
JP6330240B2 (ja) | 耐熱性β−グルコシダーゼ | |
JP6562735B2 (ja) | 新規キシラナーゼ | |
JP6340647B2 (ja) | 超耐熱性セロビオハイドロラーゼ | |
Bien et al. | Secretion of heterologous thermostable cellulases in Bacillus subtilis | |
JP6319907B2 (ja) | 耐熱性β―キシロシダーゼ | |
WO2019163886A1 (ja) | 変異β-グルコシダーゼ | |
JP6441330B2 (ja) | 熱安定性が改善されたセロビオハイドロラーゼ | |
WO2014061763A1 (ja) | 新規キシラナーゼ | |
JP6508852B2 (ja) | 改変型キシラナーゼ | |
JP6332584B2 (ja) | Acremoniumcellulolyticus(アクレモニウム・セルロリティカス)由来のβ−グルコシダーゼ及びその利用 | |
JP7051492B2 (ja) | 変異β-グルコシダーゼ | |
JP2017175958A (ja) | 耐熱性セロビオハイドロラーゼ | |
US20220356499A1 (en) | Endoglucanase, and use thereof | |
JP7250282B2 (ja) | 新規β-グルコシダーゼ、これを含む酵素組成物およびこれらを用いた糖液の製造方法 | |
WO2015076260A1 (ja) | 耐熱性キシラナーゼ | |
EP3133155B1 (en) | Hyperthermostable endoglucanase | |
JP6531974B2 (ja) | 耐熱性セロビオハイドロラーゼ | |
JP6164744B2 (ja) | ソフトバイオマスの分解方法 | |
JP2019193669A (ja) | 新規キシラナーゼ | |
JP2019195303A (ja) | キシラナーゼ及びその利用 | |
JP2008193990A (ja) | 改良耐熱性セルラーゼ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15799719 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016523493 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15313784 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15799719 Country of ref document: EP Kind code of ref document: A1 |